Open Access

miR‑320/ELF3 axis inhibits the progression of breast cancer via the PI3K/AKT pathway

  • Authors:
    • Zhiqiang Zhang
    • Jinku Zhang
    • Jinmei Li
    • Huijuan Geng
    • Bingjuan Zhou
    • Bingxin Zhang
    • Hong Chen
  • View Affiliations

  • Published online on: March 3, 2020     https://doi.org/10.3892/ol.2020.11440
  • Pages: 3239-3248
  • Copyright: © Zhang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

There is increasing evidence demonstrating that disorders affecting microRNAs (miRs) influence tumorigenesis and progression, which results in a poor prognosis in patients with breast cancer (BC). In the present study, the precise molecular mechanism underlying the role of miR‑320 in the progression of BC was investigated. Reverse transcription‑quantitative PCR was conducted to determine mRNA expression, and western blot analysis was used to test protein levels. An MTT assay was conducted to detect cell viability and Transwell assays were used to analyze cell migration and invasion abilities. Furthermore, E74‑like factor 3 (ELF3) protein density was tested via immunohistochemistry. Tumor volume was detected by xenograft tumor formation assay. The current results indicated that miR‑320 expression was downregulated in BC tissues and cells, and was associated with a poor prognosis of patients with BC. Overexpression of miR‑320 inhibited cell proliferation, migration and invasion via inhibition of the epithelial‑mesenchymal transition and the PI3K/AKT signaling pathway in BC cells. Furthermore, it was revealed that the tumor size and weight were smaller in nude mice that had been transfected to overexpress miR‑320. The luciferase reporter assay demonstrated the direct binding of miR‑320 to the 3' untranslated region of ELF3 mRNA, which may further downregulate ELF3. Overall, the present results provided evidence that miR‑320 may be a tumor suppressor in BC, and that the miR‑320/ELF3 axis regulated tumor progression via the PI3K/AKT signaling pathway, which may represent a novel treatment strategy for BC.
View Figures
View References

Related Articles

Journal Cover

April-2020
Volume 19 Issue 4

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Zhang Z, Zhang J, Li J, Geng H, Zhou B, Zhang B and Chen H: miR‑320/ELF3 axis inhibits the progression of breast cancer via the PI3K/AKT pathway. Oncol Lett 19: 3239-3248, 2020
APA
Zhang, Z., Zhang, J., Li, J., Geng, H., Zhou, B., Zhang, B., & Chen, H. (2020). miR‑320/ELF3 axis inhibits the progression of breast cancer via the PI3K/AKT pathway. Oncology Letters, 19, 3239-3248. https://doi.org/10.3892/ol.2020.11440
MLA
Zhang, Z., Zhang, J., Li, J., Geng, H., Zhou, B., Zhang, B., Chen, H."miR‑320/ELF3 axis inhibits the progression of breast cancer via the PI3K/AKT pathway". Oncology Letters 19.4 (2020): 3239-3248.
Chicago
Zhang, Z., Zhang, J., Li, J., Geng, H., Zhou, B., Zhang, B., Chen, H."miR‑320/ELF3 axis inhibits the progression of breast cancer via the PI3K/AKT pathway". Oncology Letters 19, no. 4 (2020): 3239-3248. https://doi.org/10.3892/ol.2020.11440